The July Digital Pathology Round-up with Imogen Fitt of Signify Research is here.

Nucleai and Proscia Partnership: Nucleai and Proscia have partnered to integrate Nucleai's AI Predictive Biomarker algorithms into Proscia's Concentriq platform. This collaboration aligns with the rising interest in digital companion diagnostics (CDx) in clinical trials and diagnostics. The demand for imaging biomarkers is driving rapid investments, especially from pharmaceutical companies, which will influence the digitization of clinical labs. Proscia also updated its digital pathology software, adding DICOM image support and a multi-AI overlay feature, enabling the use of multiple AI tools in the pathology workflow.

UK Pathology and Genomics Collaboration: The National Pathology Imaging Co-operative (NPIC) partnered with CellPath to install two Whole Slide Imaging (WSI) scanners, connecting them to NPIC's national digital pathology system. These scanners will create a digital archive for the 100,000 Genomes Project, a precision medicine initiative. This integration aims to enhance genomics research and develop prognostic algorithms for patient stratification.

Asia-Pacific Developments: 3DHISTECH announced Epredia China as its new distributor. Indica Labs announced new reseller agreements in the Asia-Pacific region, covering the Philippines, Thailand, Vietnam, and Malaysia. Indica Labs plans to pursue IVD registrations, indicating growth opportunities in the APAC region.

Generative AI in Digital Pathology: Scientists from Weill Cornell Medicine and Dana-Farber Cancer Institute developed generative AI tools based on ChatGPT for digital pathology. These tools provide accurate responses to digital pathology queries and help pathologists with PathML, a library for DP image analysis. While impactful in academic circles, concerns about accountability and regulation limit their clinical application.

Philips received 510(k) clearance for its IntelliSite Pathology Solution 5.1, signaling potential competitive dynamics in the US digital pathology market.

Funding Announcements: Scopio Labs raised $42 million in a Series D round led by Fortissimo Capital, aiming to expand globally with a focus on the US market. Clarapath secured $36 million in a Series B-1 round to commercialize its automated microtomy system, SectionStar.